Keyphrases
Pre-diabetes (pre-DM)
100%
Liraglutide
100%
Randomized Clinical Trial
100%
Clozapine
100%
Patients with Schizophrenia
100%
Schizophrenia Spectrum Disorders
100%
Olanzapine
100%
Overweight or Obesity
100%
Placebo
62%
Cardiometabolic Disease
37%
Glucose Tolerance
37%
Normal Glucose Tolerance
12%
Gastrointestinal Tract
12%
Drug Therapy
12%
Glucagon-like
12%
Adverse Events
12%
Antipsychotic-induced Weight Gain
12%
Receptor Agonist
12%
Weight Parameter
12%
A1 Receptor
12%
Once-daily
12%
Lipoprotein Levels
12%
Visceral Fat
12%
Clinical Site
12%
75-g Oral Glucose Tolerance Test
12%
High Mortality Rate
12%
Cardiovascular Disease
12%
Subcutaneous Injection
12%
Efficacy Analysis
12%
Systolic Blood Pressure
12%
Changes in Body Weight
12%
Schizophrenia Treatment
12%
Low-density Lipoprotein
12%
Double-blind Trial
12%
Placebo Groups
12%
Body Mass Index
12%
Denmark
12%
Medicine and Dentistry
Schizophrenia Spectrum Disorder
100%
Obesity
100%
Clozapine
100%
Liraglutide
100%
Randomized Clinical Trial
100%
Impaired Glucose Tolerance
100%
Olanzapine
100%
Placebo
75%
Glucose Tolerance
50%
Body Weight
25%
Drug Therapy
12%
Antipsychotic
12%
Cardiovascular Disease
12%
Visceral Fat
12%
Population
12%
Subcutaneous Injection
12%
Systolic Blood Pressure
12%
Treatment of Schizophrenia
12%
Body Mass Index
12%
Adverse Event
12%
Low-Density Lipoprotein
12%
Glucagon-Like Peptide-1 Agonist
12%
Patient Population
12%
Mortality Rate
12%
Oral Glucose Tolerance Test
12%
Gastrointestinal Tract
12%
Pharmacology, Toxicology and Pharmaceutical Science
Olanzapine
100%
Liraglutide
100%
Clozapine
100%
Randomized Clinical Trial
100%
Schizophrenia Spectrum Disorder
100%
Obesity
100%
Impaired Glucose Tolerance
100%
Placebo
75%
Subcutaneous Injection
12%
Low Density Lipoprotein
12%
Antipsychotic
12%
Cardiovascular Disease
12%
Glucagon Like Peptide 1 Receptor Agonist
12%
Adverse Event
12%
Mortality Rate
12%
Pharmacotherapy
12%